On Friday, UBS adjusted its outlook on InMode Ltd . (NASDAQ:INMD), a medical technology company, by reducing its price target from $26.00 to $20.00. The firm has decided to maintain a Neutral rating on the stock. This change comes in response to InMode's recent performance, which included a significant miss on operating margins.
InMode's operating margin fell short of expectations, coming in at 27.5% compared to the anticipated 40% or more. Despite the lower-than-expected top-line figures, which had been preannounced, the magnitude of the operating margin miss was not fully anticipated.
UBS noted that InMode has sufficient financial flexibility to continue investing in its business as usual, despite the ongoing and potentially intensifying macroeconomic challenges. This strategic positioning is expected to benefit the company once the economic climate becomes more favorable.
However, the current lack of clarity regarding when the macroeconomic situation might improve poses a challenge for InMode. This uncertainty makes it difficult for analysts and investors to have confidence in the company's potential for sales growth or operating margin expansion as the year progresses.
The analyst from UBS highlighted that even with revised guidance for sales, operating margins, and earnings per share (EPS) that reflect lower expectations, there remains a risk for InMode's performance extending into 2024. Consequently, the firm has reiterated its Neutral stance on the company's shares.
InvestingPro Insights
In light of UBS's recent adjustments to InMode Ltd. (NASDAQ:INMD), it's valuable to consider additional financial metrics and analyst insights. According to real-time data from InvestingPro, InMode's market capitalization stands at approximately $1.47 billion, with a notably low price-to-earnings (P/E) ratio of 8.17. This suggests that the stock may be trading at a discount relative to its near-term earnings growth potential. Moreover, the company's P/E ratio has slightly adjusted to 8.11 over the last twelve months as of Q1 2024, paired with a PEG ratio of 0.34, indicating a favorable growth outlook in comparison to its earnings multiple.
From a valuation perspective, InMode's price to book ratio is at 1.8, which could appeal to value investors looking for assets priced below their intrinsic value. The firm's strong gross profit margin of 83.1% over the last twelve months further reinforces its financial health.
On the analyst front, there are mixed InvestingPro Tips to consider: InMode holds more cash than debt on its balance sheet, and liquid assets exceed short-term obligations, which is a positive sign of financial stability. However, four analysts have revised their earnings downwards for the upcoming period, which may warrant caution. Additionally, it's worth noting that InMode is trading near its 52-week low, yet analysts predict the company will remain profitable this year. With these insights, investors can better gauge the balance between risk and opportunity.
For those looking to delve deeper into InMode's financials and future prospects, InvestingPro offers a wealth of additional tips. In fact, there are 10 more InvestingPro Tips available for InMode, which can be accessed by visiting https://www.investing.com/pro/INMD. To enhance your investing strategy, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.